A phase 1 study of AMG 900, an orally administered pan‐aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Mikkael A. Sekeres(Cleveland Clinic)American Journal of HematologyMarch 28, 201710.1002/ajh.24736Cited by 35SaveCiteExport RISWatch citationsRelated PapersLong-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial|Leukemia|2016|849Acute myeloid leukemia: current progress and future directions|Blood Cancer Journal|2021|750Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance|Blood|2007|744A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia|Acta Haematologica|2018|18